Correspondence to Author: Seili Zhang,  P.R.China

Abstract:

Objective: To assess the bodily fluid levels of galectin-3(GAL-3) in patients with body part cancer and healthy subjects. For this purpose, a prospective analysis was performed on bodily fluid specimens from forty patients with body part cancer and forty healthy subjects.

Methods: Enzyme-Linked Immune material Assay (ELISA) was accustomed live levels of galectin-3. bodily fluid levels of GAL-3 were compared between patients with body part cancer and healthy management.

Results: The (mean ± SD) GAL-3 level of healthy controls was 4.26 ± 5.8 (ng/ml) and within the CRC patients was 5.46 ± 6.3 (ng/ml). the extent of GAL-3 in CRC was slightly enhanced compared to regulate cluster, however no statistically vital variations were discovered once comparison GAL-3 bodily fluid levels between patients with body part cancer and healthy management (p values = 0.38). Hence, within the results of mythical monster curve, the surface underneath the GAL-3 curve in keeping with the larger take a look at result indicates a lot of positive take a look at (AUC = 0.58) indicates that GAL-3 assay has not sensitivity and specificity as biomarker for identification of the body part cancer.

Conclusion: we have a tendency to all over that the measuring of GAL-3 levels can’t be thought of as a prognostic biomarker for body part cancer, still additional basic and clinical analysis is required to clarify role of GAL-3.

Citation:

Seili Zhang. Evaluation of Galactin-3 Levels in Patients with large intestine Cancer and management Subjects. World Journal of Medical Oncology 2020.